Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis.
By S. Chatterjee, A. Chakraborty, I. Weinberg, Mitul B. Kadakia, R. Wilensky, Partha Sardar, D. Kumbhani, D. Mukherjee, M. Jaff, Jay S Giri. Journal of the American Medical Association (JAMA), 2014
710 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Neurology
View Paper: https://www.semanticscholar.org/paper/15e3296d58bc63e6018dde756f4cd4d0733dbaed
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Internal Medicine
Citations in the corpus
- A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. (2015, result): “Metaanalyses of trials of systemic fibrinolysis for acute PE have demonstrated similar findings (6,7).”
- Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, methodology): “See Table 1 and 4 legends for expansion of abbreviations and GRADE Working Group grades of evidence. aLow number of events. bEstimate from Chatterjee et al.147 Other estimates from meta-analyses on this topic include Dong et al:238 OR, 0.89 (0.45-1.78); Cao et al:239 RR, 0.64 (0.29-1.40); Marti et a”
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, neutral): “It is important to note that there are minimal available data demonstrating lower mortality from routine use of advanced VTE therapies (91,92).”